17 completed, 1 not yet recruiting, 1 recruiting. 19 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 17, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Typhoid Fever: new trials by email Literature Review of Typhoid Fever trials Research Report on Typhoid Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program Curcumin extract, Ciprofloxacin, Placebo - Typhoid Carrier, Typhoid Fever | Phase 2 | Not yet recruiting | Universitas Sebelas Maret | 100 | 2026-11-02 | 2026-10-30 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV - Salmonella Infections | Phase 2 | Recruiting | GlaxoSmithKline | 537 | 2026-04-01 | 2026-04-20 |
| Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever Levofloxacin, ciprofloxacin - Typhoid, Fever | Phase 2 | Completed | Avicenna Medical College Lahore | 360 | 2025-02-07 | 2025-09-02 |
| Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM - Typhoid | Phase 2 | Completed | Kathleen Neuzil | 147 | 2024-08-17 | 2026-06-03 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV) - Typhoid | Phase 2 | Completed | University of Maryland, Baltimore | 251 | 2018-12-03 | 2025-05-30 |
| Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution - Typhoid | Phase 2 | Completed | International Vaccine Institute | 285 | 2018-04-18 | 2021-08-27 |
| Vaccines Against Salmonella Typhi Vi-TCV, Vi-PS Vaccine, Control (Men ACWY) - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 112 | 2015-09-01 | 2022-07-05 |
| Understanding Typhoid Disease After Vaccination Vaccine placebo (excipients only), Ty21a, M10ZH09 vaccine - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 99 | 2011-10-07 | 2023-05-06 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine - Typhoid Fever | Phase 2 | Completed | Novartis | 120 | 2011-10-01 | 2014-04-10 |
| Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults NVGH Vi-CRM197 - Typhoid Fever | Phase 2 | Completed | Novartis | 51 | 2011-10-01 | 2014-03-24 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine - Typhoid Fever | Phase 2 | Completed | Novartis | 200 | 2011-03-01 | 2014-05-01 |
| Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg - Typhoid Fever | Phase 2 | Completed | Novartis | 88 | 2010-10-01 | 2014-01-17 |
| Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3) - Typhoid | Phase 2 | Completed | Emergent BioSolutions | 187 | 2008-05-01 | 2024-04-09 |
| Studies of Immune Responses to Orally Administered Vaccines in Developing Country Placebo, Control, Zinc Sulphate - Cholera, Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 1016 | 2008-02-01 | 2011-07-12 |
| Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Ty800 (Salmonella typhi) Oral Vaccine - Typhoid Fever | Phase 2 | Completed | Avant Immunotherapeutics | 180 | 2007-07-01 | 2008-07-02 |
| Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants Vi-rEPA conjugate vaccine for typhoid fever, Hib-TT, DTP - Typhoid Fever | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 301 | 2006-07-01 | 2012-06-27 |
| TY800 Dose Escalation (Typhoid) Ty800, Placebo - Typhoid and Paratyphoid Fevers | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 47 | 2006-02-01 | 2011-06-10 |
Cholera (1) · Fever (1) · Paratyphoid Fever (1) · Salmonella Infections (1)
Bacterial Infections (19) · Bacterial Infections and Mycoses (19) · Enterobacteriaceae Infections (19) · Gram-Negative Bacterial Infections (19) · Infections (19) · Salmonella Infections (18) · Body Temperature Changes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Vibrio Infections (1)
13-valent pneumococcal vaccine (3) · Vaccines (3) · Ciprofloxacin (2) · Pneumococcal Vaccines (2) · Polysaccharides (2) · Vi polysaccharide vaccine, typhoid (2) · Albendazole (1) · Arsenic (1) · Curcumin (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · Levofloxacin (1) · Meningococcal Vaccines (1) · Poliovirus Vaccine, Inactivated (1) · Sodium Chloride (1) · Ty21a typhoid vaccine (1)
Novartis (4) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · University of Oxford (2) · Avant Immunotherapeutics (1) · Avicenna Medical College Lahore (1) · Emergent BioSolutions (1) · EuBiologics Co.,Ltd (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GlaxoSmithKline (1) · International Vaccine Institute (1) · Kathleen Neuzil (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Universitas Sebelas Maret (1) · University of Maryland, Baltimore (1)
Philippines (3) · United States (3) · Bangladesh (2) · Belgium (2) · Burkina Faso (2) · Pakistan (2) · United Kingdom (2) · India (1) · Indonesia (1) · The Gambia (1) · Vietnam (1)
Andrew J Pollard (1) · Andrew J Pollard, FRCPCH, PhD (1) · Clark McKeever, MD (1) · Farhana Khanam, MPhil, PhD (1) · Firdausi Qadri, PhD (1) · Laurens Matthew, MD (1) · Maria Rosario Capeding, MD (1) · Maria Rosario Z Capeding, MD (1) · Nurhasan Agung Prabowo, dr., Sp.PD., M.Kes. (1) · Pierre Van Damme, MD (1) · Professor Aneela Zareen, MBBS FCPS (1) · Stephen Lockhart, DM (1) · Tonang Dwi Ardyanto, Prof., dr., Sp.PK(K), Ph.D. (1)
PMID 24290843, PMID 20188175, PMID 21980445, PMID 27533046, PMID 28965718, PMID 30845330, PMID 31585725, PMID 31877141, PMID 33150320, PMID 36774331, PMID 36875126, PMID 37402153, PMID 40446606